GlassScriptPhysician profile
Justene L Mooney
NPI 1659655058
$6,574.98
in general payments reported to CMS, 2019-2025
28 companies · $2,738 in 2025
The $2,738 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $651 · 2023: $694 · 2024: $1,602 · 2025: $2,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,774 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,773.56 |
| Education | $259.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $860.01 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Abbvie INC. | $663.07 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $585.90 | 2021-2025 | Winlevi, Ilumya, Odomzo |
| Regeneron Healthcare Solutions, INC. | $557.54 | 2021-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $549.05 | 2021-2025 | |
| Ucb, INC. | $472.70 | 2025 | Bimzelx |
| Incyte Corporation | $410.45 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $291.80 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $276.93 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $224.42 | 2022-2024 | Vtama |
| Lilly USA, LLC | $220.55 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $203.98 | 2023-2025 | Otezla, Enbrel, Otezla |
| Leo Pharma INC. | $195.24 | 2024-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $194.06 | 2024-2025 | |
| Genzyme Corporation | $164.19 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.60 | 2021-2025 | Cabtreo |
| Epi Health, LLC | $92.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Journey Medical Corporation | $81.07 | 2021 | |
| Revance Therapeutics, INC. | $74.31 | 2025 | Daxxify |
| Organon LLC | $41.38 | 2025 | Vtama |
| Pfizer INC. | $36.73 | 2025 | |
| Biofrontera INC. | $33.96 | 2021-2025 | |
| Almirall LLC | $31.05 | 2024 | Seysara |
| Allergan, INC. | $20.59 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.47 | 2025 | Valchlor |
| Verrica Pharmaceuticals INC. | $14.37 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $13.73 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justene Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.